Dyne Therapeutics Inc
DYN9.400USD
+0.070+0.75%
Cierre 07/17, 16:00（ET）Cotizaciones retrasadas 15 min
1.07BCap. mercado
PérdidaP/E TTM
Más Datos de Dyne Therapeutics Inc Compañía
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Información de la empresa
Símbolo de cotizaciónDYN
Nombre de la empresaDyne Therapeutics Inc
Fecha de salida a bolsaSep 17, 2020
Fundada en2013
Director ejecutivoMr. John Cox
Número de empleados191
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 17
Dirección1560 Trapelo Road
CiudadWALTHAM
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02451
Teléfono17817868230
Sitio Webhttps://dyne-tx.com/
Símbolo de cotizaciónDYN
Fecha de salida a bolsaSep 17, 2020
Fundada en2013
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Carlo Incerti, M.D.
Dr. Carlo Incerti, M.D.
Independent Director
Independent Director
--
--
Mr. Dirk Kersten
Mr. Dirk Kersten
Independent Director
Independent Director
--
--
Dr. Doug Kerr
Dr. Doug Kerr
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
7.51%
RA Capital Management, LP
7.05%
Atlas Venture
6.62%
The Vanguard Group, Inc.
5.36%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
68.92%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
7.51%
RA Capital Management, LP
7.05%
Atlas Venture
6.62%
The Vanguard Group, Inc.
5.36%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
68.92%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
27.04%
Venture Capital
20.92%
Investment Advisor
19.50%
Hedge Fund
15.36%
Private Equity
3.46%
Research Firm
2.73%
Sovereign Wealth Fund
0.69%
Individual Investor
0.61%
Corporation
0.22%
Other
9.46%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
430
125.53M
91.24%
+6.97M
2025Q1
444
126.02M
110.93%
+6.11M
2024Q4
417
114.24M
101.08%
-7.86M
2024Q3
400
113.88M
111.83%
-6.47M
2024Q2
373
112.89M
113.78%
+7.88M
2024Q1
324
97.50M
111.98%
+21.84M
2023Q4
282
72.67M
118.28%
-4.07M
2023Q3
268
67.80M
111.02%
+90.07K
2023Q2
267
66.99M
114.89%
+4.15M
2023Q1
269
62.13M
106.57%
+3.08M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
10.35M
7.51%
+2.97M
+40.30%
Mar 31, 2025
RA Capital Management, LP
9.71M
7.05%
+3.33M
+52.24%
Mar 31, 2025
Atlas Venture
9.13M
6.62%
+1.11M
+13.86%
Mar 31, 2025
The Vanguard Group, Inc.
7.39M
5.36%
+697.86K
+10.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.26M
4.54%
+96.01K
+1.56%
Mar 31, 2025
Forbion Capital Partners
5.46M
3.96%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.19M
3.77%
-2.39M
-31.52%
Mar 31, 2025
Braidwell LP
3.62M
2.63%
+2.94M
+431.63%
Mar 31, 2025
State Street Global Advisors (US)
3.61M
2.62%
-107.73K
-2.90%
Mar 31, 2025
Citadel Advisors LLC
3.01M
2.18%
+147.81K
+5.17%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
2.39%
Virtus LifeSci Biotech Clinical Trials ETF
0.62%
Tema Neuroscience and Mental Health ETF
0.55%
SPDR S&P Biotech ETF
0.28%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
Invesco Nasdaq Biotechnology ETF
0.15%
iShares Health Innovation Active ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.12%
Optimize Strategy Index ETF
0.12%
iShares Biotechnology ETF
0.11%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción2.39%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.62%
Tema Neuroscience and Mental Health ETF
Proporción0.55%
SPDR S&P Biotech ETF
Proporción0.28%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.26%
Invesco Nasdaq Biotechnology ETF
Proporción0.15%
iShares Health Innovation Active ETF
Proporción0.14%
ProShares Ultra Nasdaq Biotechnology
Proporción0.12%
Optimize Strategy Index ETF
Proporción0.12%
iShares Biotechnology ETF
Proporción0.11%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
